Business Trip
Business Trip
Greg Kubin & Matias Serebrinsky
Palo Santo on investing in 2nd gen psychedelics and public markets
48 minutes Posted Mar 21, 2022 at 9:00 pm.
0:00
48:20
Download MP3
Show notes

In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.

In this episode, we discuss:

  • Tim’s background in healthcare finance
  • Investing in classic psychedelic compounds vs. 2nd generation compounds
  • Hallmarks of a good first meeting with a prospective investment

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank